Could an HIV drug extend life in Creutzfeldt-Jakob disease?
NCT ID NCT07482085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether efavirenz, a drug used for HIV, can help people with Creutzfeldt-Jakob disease (CJD) live longer. CJD is a rare, rapidly fatal brain disorder. The trial will enroll 246 adults and randomly assign them to receive either efavirenz or a placebo. The main goal is to see if efavirenz extends survival time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Efavirenz (an anti-HIV drug)
- What this could lead to
- If it works, this could point toward a treatment that extends survival and slows decline in people with Creutzfeldt-Jakob disease.
- What could go wrong
- This is an early Phase 3 trial, and efavirenz has not been proven effective for CJD before. The disease is rapidly fatal, and the drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CREUTZFELDT-JAKOB DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.